TY - JOUR
TI - COVID-19 severity and mortality in patients with CLL: an update of the
international ERIC and Campus CLL study
AU - Chatzikonstantinou, Thomas
AU - Kapetanakis, Anargyros
AU - Scarfo, Lydia
AU - and Karakatsoulis, Georgios
AU - Allsup, David
AU - Alonso Cabrero,
AU - Alejandro
AU - Andres, Martin
AU - Antic, Darko
AU - Baile, Monica and
AU - Baliakas, Panagiotis
AU - Bron, Dominique
AU - Capasso, Antonella and
AU - Chatzileontiadou, Sofia
AU - Cordoba, Raul
AU - Correa, Juan-Gonzalo and
AU - Cuellar-Garcia, Carolina
AU - De Paoli, Lorenzo
AU - De Paolis, Maria
AU - Rosaria
AU - Del Poeta, Giovanni
AU - Demosthenous, Christos
AU - Dimou,
AU - Maria
AU - Donaldson, David
AU - Doubek, Michael
AU - Efstathopoulou, Maria
AU - and Eichhorst, Barbara
AU - El-Ashwah, Shaimaa
AU - Enrico, Alicia and
AU - Espinet, Blanca
AU - Farina, Lucia
AU - Ferrari, Angela
AU - Foglietta,
AU - Myriam
AU - Frederiksen, Henrik
AU - Furstenau, Moritz
AU - Garcia-Marco,
AU - Jose A.
AU - Garcia-Serra, Rocio
AU - Gentile, Massimo
AU - Gimeno, Eva and
AU - Glenthoj, Andreas
AU - da Silva, Maria Gomes
AU - Gutwein, Odit and
AU - Hakobyan, Yervand K.
AU - Herishanu, Yair
AU - Angel Hernandez-Rivas, Jose
AU - and Herold, Tobias
AU - Innocenti, Idanna
AU - Itchaki, Gilad
AU - Jaksic,
AU - Ozren
AU - Janssens, Ann
AU - Kalashnikova, Olga B.
AU - Kalicinska,
AU - Elzbieta
AU - Karlsson, Linda Katharina
AU - Kater, Arnon P.
AU - Kersting,
AU - Sabina
AU - Labrador, Jorge
AU - Lad, Deepesh
AU - Laurenti, Luca and
AU - Levin, Mark-David
AU - Lista, Enrico
AU - Lopez-Garcia, Alberto and
AU - Malerba, Lara
AU - Marasca, Roberto
AU - Marchetti, Monia
AU - Marquet,
AU - Juan
AU - Mattsson, Mattias
AU - Mauro, Francesca R.
AU - Milosevic, Ivana
AU - and Miras, Fatima
AU - Morawska, Marta
AU - Motta, Marina
AU - Munir, Talha
AU - and Murru, Roberta
AU - Niemann, Carsten U.
AU - Rodrigues, Raquel Nunes
AU - and Olivieri, Jacopo
AU - Orsucci, Lorella
AU - Papaioannou, Maria and
AU - Arturo Pavlovsky, Miguel
AU - Piskunova, Inga
AU - Popov, Viola Maria and
AU - Quaglia, Francesca Maria
AU - Quaresmini, Giulia
AU - Qvist, Kristian and
AU - Reda, Gianluigi
AU - Rigolin, Gian Matteo
AU - Ruchlemer, Rosa and
AU - Saghumyan, Gevorg
AU - Shrestha, Amit
AU - Simkovic, Martin
AU - Spacek,
AU - Martin
AU - Sportoletti, Paolo
AU - Stanca, Oana
AU - Stavroyianni, Niki
AU - and Tadmor, Tamar
AU - Te Raa, Doreen
AU - Tonino, Sanne H.
AU - Trentin,
AU - Livio
AU - Van der Spek, Ellen
AU - van Gelder, Michel
AU - van Kampen,
AU - Roel
AU - Varettoni, Marzia
AU - Visentin, Andrea
AU - Vitale, Candida and
AU - Wasik-Szczepanek, Ewa
AU - Wrobel, Tomasz
AU - Yanez San Segundo, Lucrecia
AU - and Yassin, Mohamed
AU - Coscia, Marta
AU - Rambaldi, Alessandro and
AU - Montserrat, Emili
AU - Foa, Robin
AU - Cuneo, Antonio
AU - Stamatopoulos,
AU - Kostas
AU - Ghia, Paolo
JO - Leukemia Research
PY - 2021
VL - 35
TODO - 12
SP - 3444-3454
PB - SPRINGERNATURE
SN - 0145-2126
TODO - 10.1038/s41375-021-01450-8
TODO - null
TODO - Patients with chronic lymphocytic leukemia (CLL) may be more susceptible
to Coronavirus disease 2019 (COVID-19) due to age, disease, and
treatment-related immunosuppression. We aimed to assess risk factors of
outcome and elucidate the impact of CLL-directed treatments on the
course of COVID-19. We conducted a retrospective, international study,
collectively including 941 patients with CLL and confirmed COVID-19.
Data from the beginning of the pandemic until March 16, 2021, were
collected from 91 centers. The risk factors of case fatality rate (CFR),
disease severity, and overall survival (OS) were investigated. OS
analysis was restricted to patients with severe COVID-19 (definition:
hospitalization with need of oxygen or admission into an intensive care
unit). CFR in patients with severe COVID-19 was 38.4%. OS was inferior
for patients in all treatment categories compared to untreated (p <
0.001). Untreated patients had a lower risk of death (HR = 0.54, 95%
CI:0.41-0.72). The risk of death was higher for older patients and those
suffering from cardiac failure (HR = 1.03, 95% CI:1.02-1.04; HR = 1.79,
95% CI:1.04-3.07, respectively). Age, CLL-directed treatment, and
cardiac failure were significant risk factors of OS. Untreated patients
had a better chance of survival than those on treatment or recently
treated.
ER -